Clinical and basic research of CD22-CAR T cells in the treatment of hematologic malignancy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017402

Enrollment

Unknown

Registered

2018-07-28

Start date

2018-07-31

Completion date

Unknown

Last updated

2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancy

Interventions

case series:CD22-CAR T cell therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Relasped or refractory hematological malignancies with CD22 positive; 2. Expected life time is more than 12 weeks; 3. urine pregnancy test negative; 4. Voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. patients with the history of epilepsy or other CNS disease; 2. patiets with GVHD who need immunosuppressive agents; 3. Patients with prolonged QT interval time or severe heart disease; 4. Patients with active hepatitis B or C infection; 5. patients with HIV infection.

Design outcomes

Primary

Measure	Time frame
the response to CD22-CAR T cells;overall survival;disease-free survival;safety;CRS incidence;recurrence rate;	—

Countries

China

Contacts

Public ContactHuang He

the First Affiliated Hospital of Zhejiang University School of Medicine

hehuangyu@126.com+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026